EUVIMEDEUVIMED entdecken
Crossref

Review Duration and Therapeutic Value of Cancer Drugs Granted Priority Versus Nonpriority Review in the United States, European Union, and Switzerland (2010-2024)

Simon Hediger iD, Lara Welti, Camille E G Glaus, Ulrich-Peter Rohr iD, Kerstin Noelle Vokinger iD

JCO Oncology Practice · 01.04.2026

DOI: 10.1200/op-25-01270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, online erschienen am 01.04.2026. Verfasst von Simon Hediger und 4 weiteren Autor:innen. Beteiligte Einrichtung: Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law, University of Zurich, Zurich, Switzerland. Die Arbeit nennt 31 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The objective of priority review is to expedite the review duration for drugs that provide significant improvements. We analyzed the duration of regulatory review of cancer drugs granted priority versus nonpriority review and differences in the proportion of cancer drugs with high therapeutic value granted priority versus nonpriority review in the United States, European Union, and Switzerland. METHODS In this cross-sectional study, we used US Food and Drug Administration’s (FDA), European Medicines Agency's (EMA), and Swissmedic's databases to identify all new cancer drugs approved in 2010-2024, their submission and approval dates, and approval pathways. European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) and ESMO-Magnitude of Clinical Benefit Scale for Haematological Malignancies scores were calculated to assess their therapeutic value. We applied summary statistics (medians and IQR) to describe differences in review duration for priority versus nonpriority review. Review duration was calculated from submission to approval date. For estimated differences in proportions of high therapeutic value scores for drugs granted priority versus nonpriority review, we calculated classical normal 95% CIs. RESULTS In all, 144 (86%) of 168 cancer drugs were granted priority review by the FDA, 37 (25%) of 147 by EMA, and 37 (28%) of 132 by Swissmedic. Of those, the FDA reviewed 30%, EMA 5%, and Swissmedic 49% within the required time period; review duration was similar for drugs with high and low therapeutic value. The difference in the proportion of high value scores between priority and nonpriority review was –4% (95% CI, –20 to 13) for the FDA, 22% (95% CI, 6 to 38) for EMA, and 17% (95% CI,

Autor:innen und Institutionen

  • Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law, University of Zurich, Zurich, Switzerland.
  • Academic Chair for Regulation in Law, Medicine, and Technology, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
  • Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland.

ORCID-Profile: Simon Hediger, Ulrich-Peter Rohr, Kerstin Noelle Vokinger

Zitieren

APA

Hediger, S., Welti, L., Glaus, C. E. G., Rohr, U. P., & Vokinger, K. N. (2026). Review Duration and Therapeutic Value of Cancer Drugs Granted Priority Versus Nonpriority Review in the United States, European Union, and Switzerland (2010-2024). JCO Oncology Practice. https://doi.org/10.1200/op-25-01270

Vancouver

Hediger S, Welti L, Glaus CEG, Rohr UP, Vokinger KN. Review Duration and Therapeutic Value of Cancer Drugs Granted Priority Versus Nonpriority Review in the United States, European Union, and Switzerland (2010-2024). JCO Oncology Practice. 2026. doi:10.1200/op-25-01270

BibTeX
@article{Hediger2026,
  author = {Hediger, Simon and Welti, Lara and Glaus, Camille E G and Rohr, Ulrich-Peter and Vokinger, Kerstin Noelle},
  title = {Review Duration and Therapeutic Value of Cancer Drugs Granted Priority Versus Nonpriority Review in the United States, European Union, and Switzerland (2010-2024)},
  journal = {JCO Oncology Practice},
  year = {2026},
  doi = {10.1200/op-25-01270}
}
Kostenlos starten →